Please note: the information on this page is provided for informational purposes only. As of 2011, Simmons Hanly Conroy is no longer accepting cases involving NSF & Gadolinium.
Gadolinium contrast dye injections are often used for Magnetic Resonance Imaging (MRI) or Magnetic Resonance Angiography (MRA) scans. The contrast dye injections increase the contrast in the scans and help doctors spot potential problems more accurately than with the scans alone.
Unfortunately, patients with chronic kidney problems who undergo an MRI or MRA scan have had serious, life-threatening problems following the contrast dye injections. The use of gadolinium has been linked to the development of Nephrogenic Systemic Fibrosis (NSF) and Nephrogenic Fibrosing Dermopathy, two very rare conditions. NSF and NFD are almost exclusively linked to patients with kidney conditions who have had gadolinium contrast dye injections during an MRI or MRA procedure.
Health Complications and NSF/Gadolinium Lawsuits
Health complications associated with gadolinium involve the development of a serious condition, Nephrogenic Systemic Fibrosis (NSF), which has no known cure. Symptoms of NSF include:
- Burning, itchy or swollen skin
- Hardening or tightening of the skin
- Swelling of the joints
- Yellowish eyes or yellow spots on the whites of the eyes
- Red or darkish spots on the skin, stiff joints or loss of movement in the joints
- Deep pain in the hips or ribs
- Muscle weakness
For some people, it can take up to 18 months for NSF symptoms to appear after an injection. However, they usually appear much sooner. In fact, symptoms can appear as soon as two days after the MRI or MRA procedure takes place. NSF is a progressive skin disease that typically appears and progresses quickly. The seriousness of the disease is seen in patients who become confined to a wheelchair within only weeks of being diagnosed with the condition.
In 2006, the Food and Drug Administration (FDA) issued a Public Health Advisory referring to a potential link between gadolinium and NSF/NFD. The FDA had reports of 90 patients with moderate to end-stage kidney disease and who developed NSF/NFD after an MRI with gadolinium-based contrast dye.
Simmons Hanly Conroy no longer accepts NSF & gadolinium lawsuit cases. Learn more about past litigation areas of the pharmaceutical lawyers or explore more information on our current areas of litigation. Please contact us with any questions.
United States District Court Judge Dan A. Pollster named Shareholder Jayne Conroy to the Plaintiffs’ Steering Committee in the multidistrict federal litigation pending in Cleveland, Ohio. Shareholders Clint Fisher and Andrea Bierstein also have federal leadership experience with Gadolinium-Based Contrast Agents Products Liability Litigation.
I appreciate all that the Simmons firm has done for me. I’m thrilled with the result they got for me and want to say thanks to everyone there.